Selecta Biosciences, Inc.
SELB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 51.7% | -72.9% | -94.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | 0% | 0% | 88.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | $0 | $0 |
| % Margin | 0% | -7,319.1% | 0% | 236.5% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -7,942.9% | 5,330.9% | -1,610% | -147.7% |
| EPS | -1.38 | 0.51 | -0.11 | -0.2 |
| % Growth | -370.6% | 563.6% | 45% | – |
| EPS Diluted | -1.38 | 0.5 | -0.11 | -0.2 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -7,808.8% | -7,319.1% | 0% | -189.5% |